Stockscreener 앱 받기
69.88
0.30%
-0.21
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones - TipRanks
Why Belite Bio's Widening Losses Signal a High-Probability Path to Market Leadership in Retinal Therapies - AInvest
Belite Bio's Tinlarebant: A First-in-Class Therapeutic Candidate with Dual-Indication Potential in High-Value Retinal Diseases - AInvest
FDA Grants Breakthrough Status to Belite Bio's First-Ever Stargardt Disease Treatment as Phase 3 Trials Advance - Stock Titan
Belite Bio, Inc. ADR: Stock Movement Explained - TipRanks
Belite Bio Announces $15 Million Direct Offering - TipRanks
Belite Bio raises $15 million in registered direct offering - Investing.com
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
Belite Bio Experts Join Pivotal Retinal Disease Panel at Major Ophthalmology Conference - Stock Titan
New Strong Sell Stocks for August 4th - sharewise.com
Belite Bio Announces Q2 Earnings Call: Latest Updates on Novel Retinal Disease Therapeutics Pipeline - Stock Titan
New Strong Sell Stocks for July 22nd - The Globe and Mail
Belite Bio (BLTE) Expected to Announce Earnings on Friday - Defense World
Leading vs lagging indicators on Belite Bio Inc Depositary Receipt performanceDay Trading Plan with Entry Risk Management - Newser
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan
New Strong Sell Stocks For July 22nd - Barchart.com
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations - TipRanks
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy - The Manila Times
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat
Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria
Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks
Why Belite Bio’s Stock is Soaring High - TipRanks
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com
Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com
Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq
Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
0.24%
3.39%
자본화:
|
볼륨(24시간):